• Douglas D Richman.
• University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus); Director, The HIV Institute; Co- Director, San Diego Center for AIDS Research; Florence Seeley Riford Emeritus Chair in AIDS Research, CA, USA.
• Glob Health Med. 2021 Feb 28; 3 (1): 1-5.

AbstractThe speed of development and the magnitude of efficacy of recently developed vaccines directed against SARS-CoV-2 has been truly remarkable. This editorial will not summarize the highly publicized and reviewed information about the design and clinical trial results of these vaccines. Rather, I will speculate about several issues regarding i) considerations of the rollout and implementation of the multiple vaccines, ii) the use of the vaccines in ways different from those used in the registrational phase 3 studies, iii) the future both of SARS-CoV-2 in the human population and of "normal" human life returning after widespread vaccination, and iv) the implications of the success of these SARS-CoV-2 vaccines for vaccine development against other pathogens.2021, National Center for Global Health and Medicine.

3 keywords...

hide…